These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 7692074)

  • 1. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
    Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
    J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of p53 mutations with metastatic prostate cancer.
    Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
    Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and characterization of p53 mutations in clinically localized prostate cancer.
    Hall MC; Navone NM; Troncoso P; Pollack A; Zagars GK; von Eschenbach AC; Conti CJ; Chung LW
    Urology; 1995 Mar; 45(3):470-5. PubMed ID: 7879337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
    Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
    J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
    Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
    Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.
    Meyers FJ; Gumerlock PH; Chi SG; Borchers H; Deitch AD; deVere White RW
    Cancer; 1998 Dec; 83(12):2534-9. PubMed ID: 9874460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 in prostate cancer: frequent expressed transition mutations.
    Chi SG; deVere White RW; Meyers FJ; Siders DB; Lee F; Gumerlock PH
    J Natl Cancer Inst; 1994 Jun; 86(12):926-33. PubMed ID: 7515114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer.
    Dinjens WN; van der Weiden MM; Schroeder FH; Bosman FT; Trapman J
    Int J Cancer; 1994 Mar; 56(5):630-3. PubMed ID: 8314337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
    Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
    J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.
    Incognito LS; Cazares LH; Schellhammer PF; Kuban DA; Van Dyk EO; Moriarty RP; Wright GL; Somers KD
    Int J Oncol; 2000 Oct; 17(4):761-9. PubMed ID: 10995889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.
    Mottaz AE; Markwalder R; Fey MF; Klima I; Merz VW; Thalmann GN; Ball RK; Studer UE
    Prostate; 1997 Jun; 31(4):209-15. PubMed ID: 9180930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 oncogene mutations in human prostate cancer specimens.
    Voeller HJ; Sugars LY; Pretlow T; Gelmann EP
    J Urol; 1994 Feb; 151(2):492-5. PubMed ID: 7904314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma.
    Lim BH; Soong R; Grieu F; Robbins PD; House AK; Iacopetta BJ
    Int J Cancer; 1996 Jun; 69(3):200-4. PubMed ID: 8682588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
    Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
    Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay.
    Shi XB; Bodner SM; deVere White RW; Gumerlock PH
    Diagn Mol Pathol; 1996 Dec; 5(4):271-8. PubMed ID: 8955619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 gene alterations in human prostate carcinoma.
    Effert PJ; McCoy RH; Walther PJ; Liu ET
    J Urol; 1993 Jul; 150(1):257-61. PubMed ID: 8510267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
    Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.